Experimental data showed that intravenously injected HABN accumulated in tumor cells and tumor-associated myeloid cells, (possibly as a result of the enhanced permeability and retention effect and targeting of CD44, ROS effect) allowing SC144 to act: radicalizing macrophages into the M1 phenotype, inducing killing effect of CD8+ T cells, enhanced PD-L1 expression in tumor cells and inducing immunogenic cell death in vitro. The gene discussed is CD44; the disease is neoplasm.